Stroke - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Stroke - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Stroke - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 26, 23, 2, 104, 15 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 31 and 4 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

Introduction Stroke - Overview Stroke - Therapeutics Development Stroke - Therapeutics Assessment Stroke - Companies Involved in Therapeutics Development Stroke - Drug Profiles Stroke - Dormant Projects Stroke - Discontinued Products Stroke - Product Development Milestones

Companies Featured

Acorda Therapeutics Inc Acticor Biotech SAS Addex Therapeutics Ltd Affibody AB Artelo Biosciences Inc ArunA Biomedical Inc AstraZeneca Plc BioTime Inc Boehringer Ingelheim GmbH Cardax Inc Celltrion Inc CHA Bio & Diostech Co Ltd CohBar Inc Epigen Biosciences Inc Instituto Biomar SA International Stem Cell Corp Jeil Pharmaceutical Co Ltd Neurofx Inc NeuroNascent Inc NeurOp Inc New World Laboratories Inc Nipro Corp NoNO Inc Novartis AG NuvOx Pharma LLC Phoenix Biotechnology Inc PhytoHealth Corp Prolong Pharmaceuticals LLC Regeneron Pharmaceuticals Inc RegeneRx Biopharmaceuticals Inc Vect-Horus SAS Verseon Corp Zocere Inc ZZ Biotech LLC and many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bwq7nb/stroke_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005401/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 09:39 AM/DISC: 09/17/2018 09:39 AM


Update hourly